Skip to main content

Table 1 JIA disease characteristics and traditional cardiovascular risk factors

From: Arterial properties in adults with long-lasting active juvenile idiopathic arthritis compared to healthy controls

Variables JIA patients (n = 81) Controls (n = 41)
Demographics
 Male gender; n (%) 20 (25) 9 (22)
 Age (years); median (IQR) 38.6 (34.9–40.7) 37.7 (34.8–40.5)
 Disease duration (years); median (IQR) 29.3 (28.3–30.6)  
 Onset age (years); median (IQR) 8.9 (4.9–11.8)  
JIA subtype distribution
 Systemic arthritis; n (%) 4 (5)  
 RF negative polyarthritis; n (%) 11 (14)  
 RF positive polyarthritis; n (%) 5 (6)  
 Persistent oligoarthritis; n (%) 14 (17)  
 Extended oligoarthritis; n (%) 13 (16)  
 Entesitis related arthritis; n (%) 18 (22)  
 Psoriatic arthritis; n (%) 14 (17)  
 Unclassified arthritis; n (%) 2 (3)  
Current medication at 29-year follow-up
 Anti-TNF; n (%) 25 (31)  
 Metotrexat; n (%) 19 (24)  
 NSAIDs daily; n (%) 23 (28)  
 Prednisolone; n (%) 5 (6.2)  
Cardiovascular risk factors
 BMI (kg/m2); mean (SD) 25.7 (5.0) 25.3 (3.9)
 Waist circumference (cm); mean (SD) 92.7 (12.7) 92.7 (9.0)
 Daily smokers; n (%) 18 (22) 5 (12)
 CVD in first degree relative; n (%) 46 (57) 19 (46)
 Hypertension; n (%) 9 (11) 0 (0)*
 Myocardial infarction; n (%) 1 (1) 0 (0)
 Total cholesterol (mmol/L); mean (SD) 4.9 (1.1) 4.9 (0.8)
 LDL cholesterol (mmol/L); mean (SD) 3.0 (1.0) 3.0 (0.8)
 hs-CRP (mg/L); median (IQR) 1.8 (0.7–5.0) 0.7 (0.0–1.9)*
 Insulin resistance 1.1 (1.1) 0.9 (0.6)
  1. JIA Juvenile idiopathic arthritis, IQR inter-quartile range, RF rheumatoid factor, anti-TNF anti-tumor necrosis factor, NSAIDs nonsteroidal anti-inflammatory drugs, BMI body mass index, LDL low density lipoprotein, CVD cardiovascular disease, hs-CRP high sensitivity C-reactive protein
  2. * p < 0.05 compared with values in previous column